What IKDC and MOCART scores actually measure

Two numbers appear repeatedly in ChondroFiller® research — IKDC and MOCART — and understanding what each one measures makes the outcome data far easier to interpret.

IKDC stands for the International Knee Documentation Committee score. It is a patient-reported questionnaire, scored from 0 to 100, that reflects how well the knee works in daily life and sport: walking on uneven ground, climbing stairs, squatting, returning to exercise. A score of 100 represents a fully normal, symptom-free knee; a score near zero reflects severe limitation. Crucially, researchers have established a minimum clinically important difference (MCID) of 16.7 points — the threshold above which a change in score corresponds to a real, patient-felt improvement rather than statistical noise. Any gain below that figure may be measurable but is unlikely to register as meaningful in everyday life.

MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) works differently. It is an MRI-based score, also running from 0 to 100, that a radiologist derives by examining how completely a cartilage defect has filled, how smoothly repair tissue integrates with the surrounding native cartilage, and whether the surface is congruent. It captures what is structurally happening inside the joint, independent of how the patient feels on a given day.

Together, the two scores offer complementary lenses: IKDC tells you what the patient experiences; MOCART tells you what the joint looks like. Neither is specific to ChondroFiller® — both are standard instruments used across cartilage repair research internationally, which makes cross-study comparison more reliable. The sections below use both measures to describe what the evidence shows at 12 and 36 months.

IKDC at 12 months — how much function improves

Across four prospective knee cartilage defect studies synthesised in the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025), mean IKDC improvement at 12 months is approximately 30 points. Put that alongside the MCID of 16.7 — established above — and the gap is notable: the average patient in these studies improved by roughly double the threshold for a felt, real-world difference.

The most detailed single-study figure comes from the prospective post-market clinical follow-up (PMCF) study by Jerosch et al., which recorded a mean IKDC gain of 32.4 points at one year. That result sits comfortably above 30 points and clears the MCID by a margin of nearly 16 points — not a borderline finding.

All four studies are manufacturer-sponsored investigations drawn from the same CER, which is worth stating plainly. Independent replication of this scale would sharpen confidence in the signal. What partially offsets the sponsorship limitation is consistency: each of the four study populations returned a gain in the 30-point range rather than a single outlier inflating the average. The convergence in both direction and magnitude across separate cohorts lends the 12-month functional picture a degree of robustness beyond what any individual study could provide alone.

MOCART at 12 months — what MRI shows about structural repair

MRI provides the structural counterpart to what patients report on the IKDC questionnaire. European ChondroFiller® knee studies consistently return MOCART scores of 81.6 to 84.3 at 12 months. A score above 80 reflects both quantitative fill — the defect is more than 80% occupied by repair tissue — and biological incorporation, meaning the repair tissue integrates with the surrounding native cartilage rather than sitting in isolation as a discrete plug.

The maturation arc is clinically revealing. MOCART begins at a mean of 65.3 at four weeks post-injection, rising to 81.6 by 12 months. That trajectory is not incidental: it reflects how the scaffold works. ChondroFiller® acts as an acellular collagen template that recruits the patient's own progenitor cells through a process called matrix-induced chondrogenesis. Tissue consolidation takes months rather than days, and the progressive MOCART rise maps directly onto that biological timeline — the scaffold is not delivering an instant structural fix but a gradually maturing repair environment.

Across all joints studied — knee, hip, ankle, and small joints — MOCART scores span 70 to 87, consistent with the knee-specific range and suggesting the scaffold's structural performance is not confined to a single joint.

Dedicated MOCART imaging at 36 months is not separately reported in the available sources; the long-term picture is taken up in the next section through the functional data.

The 36-month picture — does improvement hold?

Three years is the durability test that most injection therapies struggle to pass. In the Jerosch et al. PMCF study, the mean functional gain recorded at 12 months did not simply hold at that level — it edged upward, with patients reaching a mean absolute IKDC score of 80.1 at 36 months. On a scale of 0 to 100, a score in that range is consistent with good-to-near-normal knee function: patients can typically manage active daily life, recreational exercise, and the kinds of loaded activities that a moderately symptomatic knee previously restricted. The result is notable precisely because many regenerative and biologic interventions show improvement in the first year that then plateaus or erodes; the Jerosch data suggests a different trajectory, with the functional signal consolidating rather than retreating as tissue maturation continues.

The structural picture at three years is less complete. As noted when reviewing the MRI data, MOCART scoring at 36 months is not separately reported in the available sources, so long-term structural durability is inferred rather than directly demonstrated.

Comparative context is also limited: no head-to-head randomised controlled trial against microfracture or autologous chondrocyte implantation (ACI) is available in the published evidence retrieved. Direct claims about whether three-year outcomes exceed those alternatives cannot be supported by what the current evidence base contains.

With over 19,000 cases performed globally across knee, hip, ankle, and small-joint applications, there is meaningful real-world scale behind these figures — though the formal studies underpinning the 36-month data remain manufacturer-sponsored investigations, a limitation independent replication would address.

Which patients tend to see the best results

The 30-point IKDC gain and MOCART scores above 80 are population means — averages drawn from patients who were suitable candidates for ChondroFiller® at the point of treatment. Not every knee cartilage problem qualifies, and understanding which characteristics tend to predict stronger outcomes helps set realistic expectations.

Defect type and size are the primary filters. ChondroFiller® is indicated for focal cartilage defects — discrete, bounded areas of damage — rather than the widespread joint-surface loss typical of advanced osteoarthritis. A well-defined lesion surrounded by healthy native cartilage provides a more favourable repair environment; a defect at the margin of diffuse thinning presents a harder biological task for any scaffold.

Lesion location and surrounding tissue quality both shape how well the collagen matrix integrates and how much functional recovery is ultimately achievable. These factors interact in ways that are difficult to predict from imaging alone, which is why patient selection remains a clinical judgement rather than a checklist a patient can apply themselves.

The regenerative signal is not confined to the knee. Hip patients in published studies recorded a mean Harris Hip Score improvement of approximately 33 points — a magnitude comparable to the knee IKDC gains — suggesting the scaffold's capacity to recruit endogenous progenitor cells translates across joint types and anatomical settings.

A consultant assessment is the natural starting point: it maps defect characteristics, surrounding cartilage health, and clinical history against the evidence before any treatment decision is made.

Getting assessed at MSK Doctors

Outcome scores are a useful guide, but they cannot determine whether ChondroFiller® is appropriate for a specific patient — that requires a structured clinical assessment.

MSK Doctors consultants evaluate defect size, joint involvement, symptom profile, and existing imaging to decide whether an injectable scaffold pathway is the right fit. Where MRI has not yet been performed, it can be arranged before any treatment is agreed; the Sleaford clinic houses an Open MRI scanner within its Regeneration Hub, which supports outpatient injectable scaffold treatments as part of the wider regenerative medicine programme.

Patients across Lincolnshire, the East Midlands, and the wider non-London catchment can be seen at either the Sleaford (NG34) or Grantham (NG31) site — no GP referral is required, and there is no NHS-style waiting list to navigate.

For anyone wanting to explore whether ChondroFiller® is suitable, an appointment can be booked directly at mskdoctors.com.